Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.25B P/E - EPS this Y 30.90% Ern Qtrly Grth -
Income -897.68M Forward P/E -8.87 EPS next Y 43.80% 50D Avg Chg 6.00%
Sales 184.34M PEG -0.02 EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 2.63 EPS next 5Y 31.20% 52W High Chg -58.00%
Recommedations 3.80 Quick Ratio 4.51 Shares Outstanding 43.10M 52W Low Chg 82.00%
Insider Own 6.43% ROA -22.30% Shares Float 31.44M Beta 1.07
Inst Own 63.27% ROE -76.83% Shares Shorted/Prior 6.35M/3.84M Price 2.04
Gross Margin 80.22% Profit Margin - Avg. Volume 23,741,956 Target Price 14.80
Oper. Margin -274.48% Earnings Date Aug 8 Volume 30,833,852 Change -12.82%
About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc. News
12/17/24 All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
12/17/24 Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
11/15/24 Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations
11/12/24 Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
11/12/24 Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing
11/05/24 Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation
11/03/24 With 48% ownership, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has piqued the interest of institutional investors
09/24/24 NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture
09/18/24 Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
09/17/24 Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology
09/04/24 Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement
08/30/24 Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
08/19/24 Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested
08/13/24 Ginkgo Bioworks Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/10/24 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported, And Analysts Assigned A US$1.11 Price Target
08/08/24 Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
08/02/24 Ginkgo Bioworks to Hold Special Meeting of Shareholders
08/01/24 Ginkgo Bioworks Announces Date of Second Quarter 2024 Results Presentation
07/16/24 Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
06/07/24 After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
DNA Chatroom

User Image WantedToRetireEarly Posted - 5 hours ago

$DNA for the longs here what’s the hoped for inflection point? What business of theirs do you hope really lifts off in 2025?

User Image WantedToRetireEarly Posted - 5 hours ago

$DNA market cap went from $15b to $500m. Maybe it’s fairly valued now even though they still don’t have a working business model with any solid recurring revenue. And last time I checked they had maybe two years of cash left before they run out. The deal with Virgin will bring in how much revenue? And it’s a POC. Haven’t got much time to prove it works and line up more customers. And has the API they created with Google brought in any real revenue or new business? I will watch from the sidelines still. Still prefer $TWST as a viable sun bio play.

User Image Geepers Posted - 1 day ago

$DNA

User Image KaaAABooOOM Posted - 1 day ago

$DNA

User Image Georgii Posted - 1 day ago

$DNA

User Image Shaffin786 Posted - 1 day ago

$DNA Using Ginkgo’s biosurveillance technology could provide Virgin Atlantic with tools to mitigate health risks, lower insurance claims, and demonstrate to insurers that the airline is investing in proactive health and safety measures, potentially resulting in reduced insurance premiums.

User Image Shaffin786 Posted - 1 day ago

$DNA • Focus on Innovation: Virgin Atlantic is committed to advancing digital health technology in aviation. • Evolving Inflight Telemedicine: Expanding inflight health services for better passenger and crew support. • Ginkgo’s Role: Virgin Atlantic supports Ginkgo in developing biosurveillance for global health monitoring. • Strategic Advantage: Positioning Virgin Atlantic as a leader in health and safety, appealing to health-conscious travelers. • Industry-Wide Impact: Sets a precedent for other airlines to adopt similar health technologies.

User Image Shaffin786 Posted - 1 day ago

$DNA Ms. Porter’s comments underline Virgin Atlantic’s strategic investment in health technology to improve passenger and crew safety. The collaboration with Ginkgo is an important step towards enhancing aviation’s resilience to health threats, positioning the airline as a leader in health-focused innovation within the industry.

User Image Shaffin786 Posted - 1 day ago

$DNA https://youtu.be/2Qi_etYHJmo?si=zhs6QZXtVihHGAdf

User Image Shaffin786 Posted - 1 day ago

$DNA Huge for Ginko ✈️ growth on its way • Aviation Market Entry: Partnership with Virgin Atlantic showcases Horizon as a tailored biosurveillance tool for global airlines. • Revenue Streams: Monetization through subscriptions, licensing, and consulting services for airlines. • Scalability: Proof of concept with Virgin Atlantic can attract other airlines worldwide. • Data Monetization: Use aggregated passenger and cargo movement data to form partnerships with governments and global health organizations. • Reputation Boost: Establishes Ginkgo as a leader in aviation biosecurity, paving the way for cross-sector expansion (e.g., logistics, cruise lines). • Public Health Collaboration: Aligns with global health initiatives, securing potential funding or grants. • Long-Term Growth: Supports broader synthetic biology and biosecurity projects, such as vaccines and diagnostics. • First-Mover Advantage: Positions Ginkgo as a critical player in the growing aviation biosecurity market.

User Image crabhunter Posted - 1 day ago

$CRSP what are some of the other names competing in the space? $VRTX $DNA $TWST $DNAD just wonderirng, because the others/sector seem to have bounced, but CRSP is a "no" https://schrts.co/mrZaeKHF

User Image prman Posted - 1 day ago

$DNA Major pharmaceutical companies set sights on AI startups | Daily Sabah https://www.dailysabah.com/business/tech/major-pharmaceutical-companies-set-sights-on-ai-startups

User Image Ciprian99 Posted - 1 day ago

$DNA Ginkgo Biosecurity is partnering with Virgin Atlantic's Passenger and Employee Health Teams to tailor its Horizon digital pathogen monitoring platform to the aviation industry’s specific needs. The ability to identify new outbreaks early and monitor any existing ones in real time is critical for an airline’s Health Team to inform crews and passengers about potential risks in destination countries and recommend mitigating actions. Collecting, validating, monitoring, and interpreting these data is exceptionally resource-intensive since they are often unstructured, of varying reliability, and frequently require epidemiological expertise to interpret. This effort-intensive and complex activity reduces the time and effort the Health Teams have to dedicate to essential strategic activities such as the development of mitigation plans and communication with decision-makers, crews, and passengers.

User Image RicardoNA Posted - 1 day ago

$DNA 😍

User Image madnessofcrowds Posted - 1 day ago

$DNA whoops

User Image amitbran Posted - 1 day ago

$PLTR $SOFI $DNA $NNDM $HYLN Why is the market so green today?

User Image ltd424 Posted - 1 day ago

$DNA With all of these virulent strains of infectious disease on the loose it's good to know that Ginkgo Biosecurity is on the job.

User Image Mp123Good Posted - 2 days ago

Does she have another leg up in her for today? $DNA

User Image Nalviation Posted - 2 days ago

$DNA Slap slap slap 💪🚀

User Image Scottydoesntreallyknow Posted - 2 days ago

$DNA anyone else take a ton of loss here and throw it into $GME

User Image Nismatik Posted - 2 days ago

$DNA wouldn’t be surprised if this is a scam like $XWEL. WOW GL dudes

User Image Dingrad Posted - 2 days ago

$DNA hello

User Image JasonLg Posted - 2 days ago

$DNA MACD, RSI and McClellan are all now aiming down

User Image JasonLg Posted - 2 days ago

$DNA Here is what I expect in the short term here

User Image THSSKS Posted - 2 days ago

$DNA tried shorting this 🐖 and accidentally bought. Out with a $14 gain on half a penny. Now shorting the 🐖

User Image JasonLg Posted - 2 days ago

$DNA The open GAP at $10.50 did fill and I'm expecting this to drop down to the lower GAP now at $9.42 before rising again

User Image JasonLg Posted - 2 days ago

$DNA And .... ... .... NO ... I wouldn't consider SHORTING this until we hit $15. Nice upper GAP at $14 needs to fill and $15 will be the area to bounce down from

User Image JasonLg Posted - 2 days ago

$DNA These are my BUYS layered all the way down to $9.42 to buy all the stock back that I just sold. Also have 1/2 my money for BUYS all the way down to the $6.20 GAP DNA loves filling GAPS

User Image JasonLg Posted - 2 days ago

$DNA Today is TRIPLE WITCHING FRIDAY Also, if a CR is not agreed upon by tonight, we may see another crash like yesterday. I prefer to sell high and get my gains and then buy more when it drops. Careful today!

User Image JasonLg Posted - 2 days ago

$DNA SOLD all at $10.50 A GAP opened on the way up at $9.42 That's my next BUY area

Analyst Ratings
TD Cowen Buy Sep 20, 24
BTIG Sell Aug 23, 24
Goldman Sachs Sell Jul 9, 24
BTIG Sell Jun 26, 24
BTIG Sell May 15, 24
Morgan Stanley Equal-Weight May 15, 24
William Blair Underperform May 10, 24
TD Cowen Outperform Mar 1, 24
Goldman Sachs Sell Jan 23, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dmytruk Mark E. See remarks See remarks Feb 01 Sell 1.21 39,569 47,878 761,737 02/06/24
Kelly Jason R See remarks See remarks Jan 03 Sell 1.55 200,000 310,000 3,894,680 01/05/24
Dmytruk Mark E. See remarks See remarks Jan 02 Sell 1.54 45,794 70,523 716,098 01/05/24
Canton Barry 10% Owner 10% Owner Dec 20 Sell 1.77 75,300 133,281 12,374,544 12/22/23
Kelly Jason R See remarks See remarks Dec 20 Sell 1.77 200,000 354,000 4,094,680 12/22/23
Shetty Reshma P. See remarks See remarks Dec 20 Sell 1.77 75,300 133,281 12,374,544 12/22/23
Canton Barry 10% Owner 10% Owner Dec 13 Sell 1.48 75,300 111,444 12,412,194 12/15/23
Kelly Jason R See remarks See remarks Dec 13 Sell 1.48 200,000 296,000 4,294,680 12/15/23
Shetty Reshma P. See remarks See remarks Dec 13 Sell 1.48 75,300 111,444 12,412,194 12/15/23
Canton Barry 10% Owner 10% Owner Dec 06 Sell 1.32 75,300 99,396 12,449,844 12/08/23
Kelly Jason R See remarks See remarks Dec 06 Sell 1.32 200,000 264,000 4,494,680 12/08/23
Shetty Reshma P. See remarks See remarks Dec 06 Sell 1.32 75,300 99,396 12,449,844 12/08/23
Dmytruk Mark E. See remarks See remarks Dec 01 Sell 1.39 42,402 58,939 676,844 12/06/23
Shetty Reshma P. See remarks See remarks Nov 29 Sell 1.4 75,300 105,420 12,487,494 12/01/23
Kelly Jason R See remarks See remarks Nov 29 Sell 1.4 200,000 280,000 4,694,680 12/01/23
Canton Barry 10% Owner 10% Owner Nov 29 Sell 1.4 75,300 105,420 12,487,494 12/01/23
Canton Barry 10% Owner 10% Owner Nov 22 Sell 1.41 75,300 106,173 12,525,144 11/27/23
Kelly Jason R See remarks See remarks Nov 22 Sell 1.41 200,000 282,000 4,894,680 11/27/23
Shetty Reshma P. See remarks See remarks Nov 22 Sell 1.41 75,300 106,173 12,525,144 11/27/23
Shetty Reshma P. See remarks See remarks Nov 08 Sell 1.4 75,300 105,420 12,600,444 11/13/23
Kelly Jason R See remarks See remarks Nov 08 Sell 1.4 200,000 280,000 5,294,680 11/13/23
Canton Barry 10% Owner 10% Owner Nov 08 Sell 1.4 75,300 105,420 12,600,444 11/13/23
HENRY CHRISTIAN O Director Director Nov 02 Sell 1.39 4,500 6,255 1,234,378 11/06/23
Dmytruk Mark E. See remarks See remarks Nov 01 Sell 1.5 37,229 55,844 634,206 11/06/23
Shetty Reshma P. See remarks See remarks Nov 01 Sell 1.43 75,300 107,679 12,638,094 11/03/23
Canton Barry 10% Owner 10% Owner Nov 01 Sell 1.43 75,300 107,679 12,638,094 11/03/23
Kelly Jason R See remarks See remarks Nov 01 Sell 1.43 200,000 286,000 5,494,680 11/03/23
Shetty Reshma P. See remarks See remarks Oct 25 Sell 1.47 75,300 110,691 12,675,744 10/27/23
Kelly Jason R See remarks See remarks Oct 25 Sell 1.47 200,000 294,000 5,694,680 10/27/23
Canton Barry 10% Owner 10% Owner Oct 25 Sell 1.47 75,300 110,691 12,675,744 10/27/23
Canton Barry 10% Owner 10% Owner Oct 18 Sell 1.65 75,300 124,245 12,713,394 10/20/23
Kelly Jason R See remarks See remarks Oct 18 Sell 1.65 200,000 330,000 5,894,680 10/20/23
Shetty Reshma P. See remarks See remarks Oct 18 Sell 1.65 75,300 124,245 12,713,394 10/20/23
Kelly Jason R See remarks See remarks Oct 11 Sell 1.71 200,000 342,000 6,094,680 10/13/23
Shetty Reshma P. See remarks See remarks Oct 04 Sell 1.64 75,300 123,492 12,788,694 10/06/23
Kelly Jason R See remarks See remarks Oct 04 Sell 1.64 200,000 328,000 6,294,680 10/06/23
Canton Barry 10% Owner 10% Owner Oct 04 Sell 1.64 75,300 123,492 12,788,694 10/06/23
HENRY CHRISTIAN O Director Director Oct 02 Sell 1.78 4,499 8,008 1,238,878 10/06/23
Dmytruk Mark E. See remarks See remarks Oct 01 Sell 1.76 42,237 74,337 586,393 10/04/23
Kelly Jason R See remarks See remarks Sep 27 Sell 1.79 200,000 358,000 6,494,680 09/29/23
Shetty Reshma P. See remarks See remarks Sep 27 Sell 1.79 75,300 134,787 12,826,344 09/29/23
Canton Barry 10% Owner 10% Owner Sep 27 Sell 1.79 75,300 134,787 12,826,344 09/29/23
Shetty Reshma P. See remarks See remarks Sep 20 Sell 1.8 75,300 135,540 12,863,994 09/22/23
Kelly Jason R See remarks See remarks Sep 20 Sell 1.8 200,000 360,000 6,694,680 09/22/23
Canton Barry 10% Owner 10% Owner Sep 20 Sell 1.8 75,300 135,540 12,863,994 09/22/23
Shetty Reshma P. See remarks See remarks Sep 06 Sell 2.18 75,300 164,154 12,939,294 09/08/23
Canton Barry 10% Owner 10% Owner Sep 06 Sell 2.18 75,300 164,154 12,939,294 09/08/23
HENRY CHRISTIAN O Director Director Sep 05 Sell 2.23 4,499 10,033 1,243,377 09/06/23
Dmytruk Mark E. See remarks See remarks Sep 01 Sell 2.24 41,417 92,774 543,585 09/06/23
Canton Barry 10% Owner 10% Owner Aug 30 Sell 2.26 75,300 170,178 12,976,944 09/01/23